实验性大鼠溃疡性结肠炎菌群失调的诊断及复方树舌的治疗观察

目的探讨对溃疡性结肠炎厌氧菌菌群失调简便检查方法,寻找有效治疗溃疡性结肠炎的中药合剂。方法用冰乙酸诱发大鼠结肠炎模型,用复方树舌中药治疗,在治疗期间分别检测每组大鼠厌氧菌代谢产物、挥发性脂肪酸的含量、了解肠厌氧菌群改变,一般切片行HE染色,观察病理变化。结果（1）模型组大鼠挥发性脂肪酸明显低于正常组（P〈0．05）;pH从第2天起升高明显高于正常对照组（P〈0．05）,各治疗组与自然恢复组比较差异有显著性（P〈0．05）。（2）自然恢复组与各用药组间的炎症评分比较P〈0．01,各治疗组间比较,树舌加丽珠肠乐组组织损伤评分小（P〈0．05）。结论（1）测定厌氧菌的代谢产物挥发性脂肪酸含量,即可对肠内厌氧菌菌群失调做出判断。（2）实验证明,复方树舌中药可作为益生元调节肠道菌群失调及黏膜的修复,对溃疡性结肠炎疗效显著。     

乳杆菌对急性溃疡性结肠炎模型小鼠的疗效观察

目的观察植物乳杆菌YXCC-1和嗜酸乳杆菌YXCC-2对小鼠急性溃疡性结肠炎(UC)的疗效。方法对这两株菌进行体外模拟胃肠环境抗性研究,并进行动物实验。采用DSS诱导的小鼠急性UC模型,将60只小鼠随机分为4组,分别为空白对照组、DSS模型组、YXCC-1组和YXCC-2组,每组15只,观察小鼠治疗前后一般情况,计算小鼠组织学损伤评分以及观察组织学病理改变。结果菌株YXCC-1、YXCC-2有一定的耐酸、耐胆盐能力,在人工肠液环境下能较好存活;灌胃菌株发酵液可显著降低UC小鼠DAI水平,明显改善结肠组织损伤。结论植物乳杆菌YXCC-1、嗜酸乳杆菌YXCC-2发酵液对小鼠溃疡性结肠炎有治疗作用,且两者疗效相当。     

Crystal structure of the passenger domain of the Escherichia coli autotransporter EspP

Autotransporters represent a large superfamily of known and putative virulence factors produced by Gram-negative bacteria. They consist of an N-terminal “passenger domain” responsible for the specific effector functions of the molecule and a C-terminal “β-domain” responsible for translocation of the passenger across the bacterial outer membrane. Here, we present the 2.5-Å crystal structure of the passenger domain of the extracellular serine protease EspP, produced by the pathogen Escherichia coli O157:H7 and a member of the serine protease autotransporters of Enterobacteriaceae (SPATEs). Like the previously structurally characterized SPATE passenger domains, the EspP passenger domain contains an extended right-handed parallel β-helix preceded by an N-terminal globular domain housing the catalytic function of the protease. Of note, however, is the absence of a second globular domain protruding from this β-helix. We describe the structure of the EspP passenger domain in the context of previous results and provide an alternative hypothesis for the function of the β-helix within SPATEs.     

DNA methylation-associated colonic mucosal immune and defense responses in treatment-na?ve pediatric ulcerative colitis

Inflammatory bowel diseases (IBD) are emerging globally, indicating that environmental factors may be important in their pathogenesis. Colonic mucosal epigenetic changes, such as DNA methylation, can occur in response to the environment and have been implicated in IBD pathology. However, mucosal DNA methylation has not been examined in treatment-naïve patients. We studied DNA methylation in untreated, left sided colonic biopsy specimens using the Infinium HumanMethylation450 BeadChip array. We analyzed 22 control (C) patients, 15 untreated Crohn’s disease (CD) patients, and 9 untreated ulcerative colitis (UC) patients from two cohorts. Samples obtained at the time of clinical remission from two of the treatment-naïve UC patients were also included into the analysis. UC-specific gene expression was interrogated in a subset of adjacent samples (5 C and 5 UC) using the Affymetrix GeneChip PrimeView Human Gene Expression Arrays. Only treatment-naïve UC separated from control. One-hundred-and-twenty genes with significant expression change in UC (> 2-fold, P < 0.05) were associated with differentially methylated regions (DMRs). Epigenetically associated gene expression changes (including gene expression changes in the IFITM1, ITGB2, S100A9, SLPI, SAA1, and STAT3 genes) were linked to colonic mucosal immune and defense responses. These findings underscore the relationship between epigenetic changes and inflammation in pediatric treatment-naïve UC and may have potential etiologic, diagnostic, and therapeutic relevance for IBD.     

双歧杆菌三联活菌胶囊对溃疡性结肠炎患者血清白介素-6、8和10水平的影响及疗效观察

目的探讨双歧杆菌三联活菌胶囊对溃疡性结肠炎（UC）患者血清白介素（IL）-6、8和10水平的影响及疗效观察。方法选取88例UC患者,随机分为观察组和对照组。两组患者均酌情予以柳氮磺胺吡啶、5-氨基水杨酸和糖皮质激素等常规治疗。观察组患者在此基础上加用口服双歧杆菌三联活菌胶囊420mg/次,3次/d,连用8周。对照组患者除不使用双歧杆菌三联活菌胶囊外余治疗同观察组。观察两组患者治疗前后血清IL-6、8和10水平变化,并比较其临床疗效及不良反应。结果治疗8周后,两组患者血清IL-6、8水平明显下降,IL-10水平明显上升（P〈0.05或P〈0.01）,且观察组下降值或上升值大于对照组（P〈0.05）;观察组患者总有效率明显高于对照组（χ2=4.42,P〈0.05）;治疗中对照组出现不良反应3例,观察组出现5例,症状均较轻,两组患者不良反应发生率比较差异无统计学意义（χ2=0.14,P〉0.05）。结论双歧杆菌三联活菌胶囊治疗UC的疗效确切,安全性较好,作用与其能降低血清IL-6、8水平,提高血清IL-10水平,减轻肠黏膜局部炎症反应密切相关。     

Modifications of mesenteric adipose tissue during moderate experimental colitis in mice

Aims

Adipose tissue secretes various proteins referred to as adipokines, being involved in inflammation. It was recognized that mesenteric adipose tissue (MAT) is altered by inflammation, and pathologies such as inflammatory bowel disease (IBD). The aim of this study was to investigate the alterations of the mesenteric adipose tissue in two experimental colitis models in mice adapted to obtain moderate colonic inflammation.

Main methods

Colonic inflammation was obtained using two models, either DSS dissolved in drinking water or intra-colonic instillation of DNBS. The expression of adipokines (leptin and adiponectin) and inflammatory markers (IL-6, MCP-1, F4/80) was studied by qRT-PCR in the MAT of treated and control mice.

Key findings

Observations of the colon and IL-6 plasma level determination demonstrated that DNBS treatment led to stronger inflammation. Colitis induced a decrease of mRNA encoding to leptin and adiponectin in MAT. In contrast, colonic inflammation led to an increase of mRNA encoding to IL-6, MCP-1 and F4/80, a specific marker of macrophages.

Significance

The mesenteric adipose tissue, in two models of moderate colitis, shows a loss of adipose profile and a strong increase of inflammatory pattern, close to the observations made in MAT of IBD patients. These data suggest that these pro-inflammatory modifications of MAT have to be taken into account in the pathophysiology of IBD.     

Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails

Identification of highly selective type II kinase inhibitors is described. Two different chiral peptidomimetic scaffolds were introduced on the tail region of non-selective type II kinase inhibitor GNF-7 to enhance the selectivity. Kinome-wide selectivity profiling analysis showed that type II kinase inhibitor 7a potently inhibited Lck kinase with great selectivity (IC₅₀ of 23.0 nM). It was found that 7a and its derivatives possessed high selectivity for Lck over even structurally conserved all Src family kinases. We also observed that 7a inhibited Lck activation in Jurkat T cells. Moreover, 7a was found to alleviate clinical symptoms in DSS-induced colitis mice. This study provides a novel insight into the design of selective type II kinase inhibitors by adopting chiral peptidomimetic moieties on the tail region.     

The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases

IL-17 inhibitors (IL-17i) are medicines used to treat dermatological and rheumatic diseases They belong to a class of medicines called biological disease-modifying anti-rheumatic drugs (bDMARDs). This class of drugs has had a major impact on the therapy of autoimmune diseases, being much safer and more effective than treatment with small molecules. At the same time, they have highly beneficial effects on skin and joint changes, and their efficacy has been extensively monitored and demonstrated in numerous clinical trials. More and more such drugs are still being discovered today to ensure the best possible treatment of these patients, but more frequently and relatively constantly three agents are used. Two of them (Secukinumab and Ixekizumab) inhibit IL-17A directly, and the third, Brodamulab, inhibits the IL-17A receptor. Although they are extremely effective in the treatment of these diseases, sometimes their administration has been associated with paradoxical effects, i.e., there is an exacerbation of the inflammatory process. Tough, clinical trials of IL-17i have described cases of exacerbation or even onset of inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis, after administration of these drugs in patients previously diagnosed with psoriasis (PS), psoriatic arthritis (PsA), or ankylosing spondylitis (AS). The pathophysiological mechanism of action is not well understood at present. One explanation would be that this hyperreactive inflammatory process would be triggered by Interferon 1 derived from dendritic plasma cells. Even though there are many reports in the recent literature about the role of IL17i in the onset of IBD, conclusions of studies do not converge. Some of them show an increased incidence of IBD in patients treated with IL17i, while some others affirm their safety of them. In the near future we will surely have more data emerging from ongoing meta-analyses regarding safety of use IL17i in patients who are at risk of developing IBD. Clinical and paraclinical evaluation (inflammatory intestinal markers) are carefully advised before recommending treatment with IL-17i and after initiation of treatment, and prospective surveillance by clinical and biomarkers of patients treated with IL-17i is absolutely essential to capture the onset of IBD.     

Genetic manipulation of gut microbes enables single-gene interrogation in a complex microbiome

1. Download : Download high-res image (212KB)
2. Download : Download full-size image